Pembrolizumab granted FDA Priority Review for the second-line treatment of relapsed/refractory classical Hodgkin Lymphoma

The supplemental biologics license application is based on data from the Phase III KEYNOTE-204 trial, in which pembrolizumab monotherapy was associated with improved progression-free survival when compared to brentuximab (the study will continue to evaluate overall survival).


Biospace Inc.